Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to inject some much-needed growth into its top line. But a rising debt load isn't making investors too excited about the business, despite its potential.
Below, I'll look at the company's financials, opportunities, risk, and valuation to help assess whether this is a stock worth buying today.
On Feb. 6, Amgen reported its year-end results for 2023. Revenue of $28.2 billion rose by 7% on a year-over-year basis. The results included a boost from its recent acquisition of Horizon Therapeutics, which closed in October.
Source Fool.com